{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T05:58:19Z","timestamp":1791093499479,"version":"4.1.0"},"reference-count":27,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"33","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2007,11,20]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p> We evaluated the efficacy and safety of bevacizumab in patients with platinum-resistant epithelial ovarian carcinoma (EOC) or peritoneal serous carcinoma (PSC) who had experienced disease progression during, or within 3 months of discontinuing, topotecan or liposomal doxorubicin. <\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p> No more than three prior treatment regimens were allowed. Patients received single-agent bevacizumab 15 mg\/kg intravenously every 3 weeks. Response was assessed by computed tomography (CT) scan every 6 weeks using Response Evaluation Criteria in Solid Tumors (RECIST). <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p> Of 44 patients treated, 83.7% were primarily platinum resistant, 59.1% had received liposomal doxorubicin, 25% topotecan, 15.9% both agents, and 47.7% had received three prior chemotherapy regimens. A median of five (range, two to 16) bevacizumab doses were administered. Partial responses were observed in seven patients (15.9%). Median progression-free survival was 4.4 months (95% CI, 3.1 to 5.5 months), with a median survival duration of 10.7 months at study termination. Bevacizumab-associated grade 3 to 4 events included hypertension (9.1%), proteinuria (15.9%), bleeding (2.3%), and wound-healing complications (2.3%). The incidence of GI perforation (GIP; 11.4%) was higher than reported in bevacizumab trials of other tumor types. GIP occurred in 23.8% of patients receiving three prior chemotherapy regimens, compared with 0% of patients receiving two prior chemotherapy regimens (P &lt; .01). A trend toward higher risk of GIP was observed for patients with bowel wall thickening or bowel obstruction on CT scan. Arterial thromboembolic events occurred in three patients (6.8%). Three deaths were related to bevacizumab treatment. <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p> Bevacizumab has single-agent activity in patients with platinum-resistant EOC or PSC. A higher than expected incidence of GIP was noted in these heavily pretreated patients. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2007.12.0782","type":"journal-article","created":{"date-parts":[[2007,11,16]],"date-time":"2007-11-16T23:23:52Z","timestamp":1195255432000},"page":"5180-5186","source":"Crossref","is-referenced-by-count":632,"title":["Phase II Study of Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer or Peritoneal Serous Cancer"],"prefix":"10.1200","volume":"25","author":[{"given":"Stephen A.","family":"Cannistra","sequence":"first","affiliation":[{"name":"From the Beth Israel Deaconess Medical Center; Dana-Farber Cancer Institute; Massachusetts General Hospital, Boston, MA; Genentech Inc, South San Francisco; University of California at Irvine, Orange, CA; The Johns Hopkins Kimmel Cancer Center; Franklin Square Hospital, Baltimore, MD; and Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula A.","family":"Matulonis","sequence":"additional","affiliation":[{"name":"From the Beth Israel Deaconess Medical Center; Dana-Farber Cancer Institute; Massachusetts General Hospital, Boston, MA; Genentech Inc, South San Francisco; University of California at Irvine, Orange, CA; The Johns Hopkins Kimmel Cancer Center; Franklin Square Hospital, Baltimore, MD; and Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard T.","family":"Penson","sequence":"additional","affiliation":[{"name":"From the Beth Israel Deaconess Medical Center; Dana-Farber Cancer Institute; Massachusetts General Hospital, Boston, MA; Genentech Inc, South San Francisco; University of California at Irvine, Orange, CA; The Johns Hopkins Kimmel Cancer Center; Franklin Square Hospital, Baltimore, MD; and Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Hambleton","sequence":"additional","affiliation":[{"name":"From the Beth Israel Deaconess Medical Center; Dana-Farber Cancer Institute; Massachusetts General Hospital, Boston, MA; Genentech Inc, South San Francisco; University of California at Irvine, Orange, CA; The Johns Hopkins Kimmel Cancer Center; Franklin Square Hospital, Baltimore, MD; and Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"Dupont","sequence":"additional","affiliation":[{"name":"From the Beth Israel Deaconess Medical Center; Dana-Farber Cancer Institute; Massachusetts General Hospital, Boston, MA; Genentech Inc, South San Francisco; University of California at Irvine, Orange, CA; The Johns Hopkins Kimmel Cancer Center; Franklin Square Hospital, Baltimore, MD; and Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Mackey","sequence":"additional","affiliation":[{"name":"From the Beth Israel Deaconess Medical Center; Dana-Farber Cancer Institute; Massachusetts General Hospital, Boston, MA; Genentech Inc, South San Francisco; University of California at Irvine, Orange, CA; The Johns Hopkins Kimmel Cancer Center; Franklin Square Hospital, Baltimore, MD; and Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Douglas","sequence":"additional","affiliation":[{"name":"From the Beth Israel Deaconess Medical Center; Dana-Farber Cancer Institute; Massachusetts General Hospital, Boston, MA; Genentech Inc, South San Francisco; University of California at Irvine, Orange, CA; The Johns Hopkins Kimmel Cancer Center; Franklin Square Hospital, Baltimore, MD; and Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Burger","sequence":"additional","affiliation":[{"name":"From the Beth Israel Deaconess Medical Center; Dana-Farber Cancer Institute; Massachusetts General Hospital, Boston, MA; Genentech Inc, South San Francisco; University of California at Irvine, Orange, CA; The Johns Hopkins Kimmel Cancer Center; Franklin Square Hospital, Baltimore, MD; and Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Armstrong","sequence":"additional","affiliation":[{"name":"From the Beth Israel Deaconess Medical Center; Dana-Farber Cancer Institute; Massachusetts General Hospital, Boston, MA; Genentech Inc, South San Francisco; University of California at Irvine, Orange, CA; The Johns Hopkins Kimmel Cancer Center; Franklin Square Hospital, Baltimore, MD; and Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Wenham","sequence":"additional","affiliation":[{"name":"From the Beth Israel Deaconess Medical Center; Dana-Farber Cancer Institute; Massachusetts General Hospital, Boston, MA; Genentech Inc, South San Francisco; University of California at Irvine, Orange, CA; The Johns Hopkins Kimmel Cancer Center; Franklin Square Hospital, Baltimore, MD; and Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"McGuire","sequence":"additional","affiliation":[{"name":"From the Beth Israel Deaconess Medical Center; Dana-Farber Cancer Institute; Massachusetts General Hospital, Boston, MA; Genentech Inc, South San Francisco; University of California at Irvine, Orange, CA; The Johns Hopkins Kimmel Cancer Center; Franklin Square Hospital, Baltimore, MD; and Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.57.1.43"},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra041842"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.5.1158"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.14.3312"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1997.537"},{"key":"R6","unstructured":"Abu-Jawdeh GM, Faix JD, Niloff J, et al: Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms. Lab Invest 74:1105,1996-1115,"},{"key":"R7","unstructured":"Byrne AT, Ross L, Holash J, et al: Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin Cancer Res 9:5721,2003-5728,"},{"key":"R8","unstructured":"Alvarez AA, Krigman HR, Whitaker RS, et al: The prognostic significance of angiogenesis in epithelial ovarian carcinoma. Clin Cancer Res 5:587,1999-591,"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19960621)69:3<205::AID-IJC10>3.0.CO;2-6"},{"key":"R10","unstructured":"Hollingsworth HC, Kohn EC, Steinberg SM, et al: Tumor angiogenesis in advanced stage ovarian carcinoma. Am J Pathol 147:33,1995-41,"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1097\/00004347-199707000-00011"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19970701)80:1<98::AID-CNCR13>3.0.CO;2-A"},{"key":"R13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.3.843"},{"key":"R14","doi-asserted-by":"crossref","unstructured":"Burger RA, Sill M, Monk B, et al: Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer: A Gynecologic Oncology Group (GOG) study. J Clin Oncol 23:457s,2005,  (suppl; abstr 5009)","DOI":"10.1200\/jco.2005.23.16_suppl.5009"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.129"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.3.205"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.20.4054"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-9473(99)00015-8"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021491"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.08.955"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2003.08.013"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061884"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.3816\/CBC.2003.n.007"},{"key":"R24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032691"},{"key":"R25","unstructured":"AVASTIN package insert . South San Franciso, CA, Genentech Inc, 2005"},{"key":"R26","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21969"},{"key":"R27","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2005.23.16_suppl.3020"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2007.12.0782","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T20:14:19Z","timestamp":1653509659000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2007.12.0782"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,11,20]]},"references-count":27,"journal-issue":{"issue":"33","published-print":{"date-parts":[[2007,11,20]]}},"alternative-id":["10.1200\/JCO.2007.12.0782"],"URL":"https:\/\/doi.org\/10.1200\/jco.2007.12.0782","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,11,20]]}}}